Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases

Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases

Saved in:

Bibliographic Details
Main Authors:	E. Ayad, M. Mansy, D. Elwi, M. Salem, M. Salama, K. Kayser
Format:	Article
Language:	English
Published:	Wiley 2014-01-01
Series:	Analytical Cellular Pathology
Online Access:	http://dx.doi.org/10.1155/2014/608254
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing
by: Tim S. Poulsen, et al.
Published: (2013-01-01)

Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
by: Solmaz AghaAmiri, et al.
Published: (2021-01-01)

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
by: Cathy B. Moelans, et al.
Published: (2009-01-01)

Groping for Quantitative Digital 3-D Image Analysis: An Approach to Quantitative Fluorescence In Situ Hybridization in Thick Tissue Sections of Prostate Carcinoma
by: Karsten Rodenacker, et al.
Published: (1997-01-01)

Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
by: Maria Savino, et al.
Published: (2009-01-01)

Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)

HER2 Negative Mammary Paget’s Disease or In Situ Melanoma? A Case Report and Review of the Literature
by: Luana-Andreea Boșoteanu, et al.
Published: (2023-01-01)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024-01-01)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
by: Hope S Rugo, et al.
Published: (2022-01-01)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
by: Maria Antonietta Lucci, et al.
Published: (2010-01-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
by: Maria Elena Lacruz, et al.
Published: (2025-02-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer
by: Wei Lv, et al.
Published: (2018-01-01)

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
by: Ovidiu Balacescu, et al.
Published: (2016-01-01)

Immunocytochemistry and DNA-image Cytometry in Diagnostic Effusion Cytology. II. Diagnostic Accuracy in Equivocal Smears
by: Helma Motherby, et al.
Published: (1999-01-01)

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer
by: Akshara Singareeka Raghavendra, et al.
Published: (2025-01-01)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
by: Tryambak Pratap Srivastava, et al.
Published: (2025-01-01)

Reflectance Confocal Microscopy as an Aid to Dermoscopy to Improve Diagnosis on Equivocal Lesions: Evaluation of Three Bluish Nodules
by: Sara Bassoli, et al.
Published: (2010-01-01)

A Study Comparing Immunohistochemistry, Fluorescence in situ hybridization, GeneXpert® Breast Cancer STRAT4 Assay for Determining Hormone Receptor, Human Epidermal Growth Factor Receptor 2, Ki67 Status in Invasive Breast Carcinoma in Moroccan women
by: Rajaa El Aje, et al.
Published: (2023-06-01)

VISUALIZATION OF CHROMOSOME-SPECIFIC DNA SEQUENCES BY FLUORESCENCE IN SITU HYBRIDIZATION OF MICRODISSECTION DNA PROBES WITH METAPHASE CHROMOSOMES
by: A. G. Bogomolov, et al.
Published: (2014-12-01)

Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
by: Claire Corcoran, et al.
Published: (2025-01-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01)

Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation
by: Farnaz Khaleseh, et al.
Published: (2021-05-01)

HER2-Positive Metaplastic Spindle Cell Carcinoma Associated with Synchronous Bilateral Apocrine Carcinoma of the Breast
by: Katsumi Kito, et al.
Published: (2014-01-01)

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
by: Xinpei Deng, et al.
Published: (2024-09-01)

Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years
by: Frederik K. Palshof, et al.
Published: (2025-02-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)